Prevalence of Pain In Depressed Patients and Its Impact on Treatment Outcomes

Authors

  • Muhammad Awais Combined Military Hospital, Okara, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v6i10.2066

Keywords:

Depression, Chronic pain, Collaborative care, Treatment outcomes, Pain interference, HSCL-20, SF-36, Major depressive disorder, Integrated management

Abstract

Depression and pain frequently co-occur, sharing overlapping neurobiological mechanisms that can amplify symptom severity and hinder treatment efficacy. Chronic pain among individuals with depression substantially affects their functional outcomes and quality of life, yet integrated management approaches remain underutilized. This study aimed to determine the prevalence of pain in patients with depression and evaluate its impact on treatment outcomes. Methods: This prospective, randomized controlled trial was conducted over six months at the psychiatric outpatient department of a tertiary-care teaching hospital. A total of 200 adults diagnosed with Major Depressive Disorder or Persistent Depressive Disorder (DSM-V criteria) were enrolled and randomly assigned to either an intervention group receiving structured collaborative care or a control group receiving standard care. Depression severity was assessed using the Hopkins Symptom Checklist-20 (HSCL-20), and pain interference was evaluated through the Short Form-36 (SF-36) pain subscale at baseline, 3 months, and 6 months. Data were analyzed using repeated-measures ANOVA and multivariate regression to identify predictors of depression outcomes. Results: At baseline, 42% of participants reported moderate to severe pain interfering with daily activities. Both groups showed significant improvements in HSCL-20 and SF-36 scores over six months (p < 0.001). The intervention group exhibited greater improvement in depressive symptoms (p = 0.03), while pain reduction was comparable between groups (p = 0.41). Despite overall progress, 32% of patients continued to report moderate pain at 6 months. Regression analysis revealed that baseline pain severity and reduction in pain over time significantly predicted depression remission (p < 0.001). A significant interaction between pain reduction and treatment group was observed (p = 0.027), suggesting that integrated care enhanced depression recovery independent of pain persistence. Conclusion: Pain is highly prevalent among patients with depression and significantly influences treatment outcomes. Although depressive symptoms improved in both study groups, persistent pain remained in a substantial subset, underscoring the need for integrated, multidisciplinary approaches addressing both mood and pain symptoms concurrently. Collaborative care demonstrated superior efficacy in improving depression, supporting its adoption in clinical practice to optimize holistic recovery.

Downloads

Download data is not yet available.

References

Zhou C., Wu Y., Ding X., Shi N., Cai Y., & Pan Z. Sirt1 reduces emotional pain vulnerability by promoting deacetylation of Camkiiα in the central amygdala. Journal of Neuroscience 2020;40(11):2332-2342. https://doi.org/10.1523/jneurosci.1259-19.2020

Li H., Song Q., Zhang R., Zhou Y., & Kong Y.. Enhanced temporal coupling between the thalamus and the dorsolateral prefrontal cortex mediates chronic low back pain and depression. Neural Plasticity 2021;2021:1-10. https://doi.org/10.1155/2021/7498714

Flores-García M., Rizzo A., Garçon-Poca M., Fernández‐Dueñas V., & Bonaventura J. Converging circuits between pain and depression: the ventral tegmental area as a therapeutic hub. Frontiers in Pharmacology 2023;14. https://doi.org/10.3389/fphar.2023.1278023

Zhou Y., Wang C., Lan X., Li H., Chao Z., & Ning Y.. Plasma inflammatory cytokines and depressed patients with comorbid pain: improvement by ketamine. 2021. https://doi.org/10.21203/rs.3.rs-595708/v1

Lan X., Zhou Y., Wang C., Li W., Zhang F., Liu H., et al.. Pre-treatment pain symptoms influence antidepressant response to ketamine in depressive patients. Frontiers in Psychiatry 2022;13. https://doi.org/10.3389/fpsyt.2022.793677

Bonilla‐Jaime H., Sánchez-Salcedo J., Estévez-Cabrera M., Molina‐Jiménez T., Cortes-Altamirano J., & Alfaro-Rodríguez A. Depression and pain: use of antidepressants. Current Neuropharmacology 2022;20(2):384-402. https://doi.org/10.2174/1570159x19666210609161447

Hsu Y., Ma K., Guo S., Lin B., Tsai C., & Yeh C.. The occurrence of pain-induced depression is different between rat models of inflammatory and neuropathic pain. Journal of Clinical Medicine 2021;10(17):4016. https://doi.org/10.3390/jcm10174016

Sachau J., Kersebaum D., Hüllemann P., Adolf D., Kabelitz M., Keller T.et al. The association of self-reported symptoms of central sensitization and sleep disturbances in neuropathic pain. Pain Reports 2023;8(5):e1098. https://doi.org/10.1097/pr9.0000000000001098

Roughan W., Campos A., García‐Marín L., Cuéllar-Partida G., Lupton M., Hickie I.et al. Comorbid chronic pain and depression: shared risk factors and differential antidepressant effectiveness. 2020. https://doi.org/10.1101/2020.05.23.20110841

Ayzenberg I., Richter D., Henke E., Asseyer S., Paul F., Trebst C.et al. Pain, depression, and quality of life in neuromyelitis optica spectrum disorder. Neurology Neuroimmunology & Neuroinflammation 2021;8(3). https://doi.org/10.1212/nxi.0000000000000985

Chérif F., Zouari H., Cherif W., Hadded M., Cheour M., & Damak R. Depression prevalence in neuropathic pain and its impact on the quality of life. Pain Research and Management 2020;2020:1-8. https://doi.org/10.1155/2020/7408508

Wang W., Wang Y., Wang F., Chen H., Qin X., Yang L.et al.. Notable dysthymia: evolving trends of major depressive disorders and dysthymia in china from 1990 to 2019, and projections until 2030. BMC Public Health 2024;24(1). https://doi.org/10.1186/s12889-024-18943-7

Zisook S., Johnson G., Hicks P., Chen P., Beresford T., Michalets J.et al.. Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: a VAST-D report. Depression and Anxiety 2020;38(2):185-195. https://doi.org/10.1002/da.23114

Cuijpers P., Noma H., Karyotaki E., Vinkers C., Cipriani A., & Furukawa T.. A network meta‐analysis of the effects of psychotherapies, pharmacotherapies, and their combination in the treatment of adult depression. World Psychiatry 2020;19(1):92-107. https://doi.org/10.1002/wps.20701

Srinivasan K., Heylen E., Pradeep R., Mony P., & Ekstrand M. Collaborative care compared to enhanced standard treatment of depression with co-morbid medical conditions among patients from rural south India: a cluster randomized controlled trial (Hope Study). BMC Psychiatry 2022;22(1). https://doi.org/10.1186/s12888-022-04000-3

Brown L., Stanton J., Bharthi K., Maruf A., Müller D., & Bousman C. Pharmacogenomic testing and depressive symptom remission: a systematic review and meta‐analysis of prospective, controlled clinical trials. Clinical Pharmacology & Therapeutics 2022;112(6):1303-1317. https://doi.org/10.1002/cpt.2748

Makino K., Lee S., Bae S., Shinkai Y., Chiba I., & Shimada H. Combined effects of pain interference and depressive symptoms on dementia incidence: a 36-month follow-up study. Journal of Alzheimer's Disease 2020;76(2):703-712. https://doi.org/10.3233/jad-191139

Scott F., Hampsey E., Gnanapragasam S., Carter B., Marwood L., Taylor R.et al.. Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. Journal of Psychopharmacology 2022;37(3):268-278. https://doi.org/10.1177/02698811221104058

Downloads

Published

2025-10-31

How to Cite

Awais, M. . (2025). Prevalence of Pain In Depressed Patients and Its Impact on Treatment Outcomes. Biological and Clinical Sciences Research Journal, 6(10), 37–41. https://doi.org/10.54112/bcsrj.v6i10.2066

Issue

Section

Original Research Articles

Most read articles by the same author(s)